Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Neovasc Inc. NVCN

Healthcare Medical Instruments & Supplies
Neovasc Inc is a specialty medical device company. It develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products the Neovasc Reducer (Reducer), for the treatment of refractory angina, which is not currently commercially available in the United States and has been commercially available in Europe since 2015, and the Tiara, for the transcatheter treatment of mitral valve disease, which is under clinical investigation in the United States, Canada, Israel and Europe. The company earns revenue from one source, the Reducer.


NDAQ:NVCN - Post by User

Neovasc Inc. > These "price targets" by Analysts
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(0)
•••
Comment by onions7777on Apr 11, 2018 10:17am
71 Views
Post# 27865769

RE:RE:RE:These "price targets" by Analysts

RE:RE:RE:These "price targets" by AnalystsAnalysts hate to be wrong. The positive side is analysts are rating a stock under 10 cents. Thats Rare. Some of these targets are possible but very unlikely in the short term. Im not an analyst, but from experience I see this stock @.15-.20 by the end of June, and .50-.65 by the end of the year.

Obviously a Buy Out or positive Press Releases will change things. Just keep your ears open and react accordingly.




<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities